drugset / Trial / NCT05837455
NeoTAILOR: ABiomarker-directed Approach to Guide Neoadjuvant Therapy for Patients With Stage II/III ER-positive, HER2-negative Breast Cancer
Phase 2
Recruiting
81 enrolled
Washington University School of Medicine
Swim Across America · collabThe Foundation for Barnes-Jewish Hospital · collab
Non-randomizedParallel-groupOpen-labelTreatment
Summary
This study aims to utilize a novel biomarker-driven approach to guide neoadjuvant treatment selection. It is the hypothesis that this will improve clinical response for postmenopausal women with clinical stage II/III ER-positive, HER2-negative breast cancer and identify those who may not require neoadjuvant chemotherapy, with a primary focus on outcomes in Black patients.
Timeline
- Start
- 2024-05-30
- Primary completion
- 2027-11-30
- Completion
- 2027-11-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Anastrozole | Other / unclassified | — | — |